ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cystic Fibrosis Foundation announces $500 million in research funding

by Ryan Cross
November 2, 2019 | APPEARED IN VOLUME 97, ISSUE 43

With the launch of the cystic fibrosis drug Trikafta, about 90% of people with the disease have a treatment. The Cystic Fibrosis Foundation has an ambitious plan to close the gap and go beyond treatments. The nonprofit is committing $500 million to cystic fibrosis drug discovery through 2025, with a focus on not just treating but curing the disease. The funding will mostly support clinical studies of drug classes including mRNA therapy, gene therapy, and gene editing.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment